Kleefstra Syndrome — designated KS, OMIM #610253, also known as 9q34 Deletion Syndrome or Euchromatic Histone-Lysine N-Methyltransferase 1 Deficiency, a neurodevelopmental disorder characterized by moderate to severe intellectual disability, childhood hypotonia, characteristic facial features, a distinctive behavioral phenotype of apparent happy and friendly demeanor in childhood that often evolves into social withdrawal and behavioral regression in adolescence and adulthood, and a significant risk of congenital cardiac and urogenital anomalies, affecting an estimated 1 in 200,000–500,000 live births with over 800 individuals described in the literature as of the mid-2020s, caused by heterozygous loss-of-function pathogenic variants in EHMT1 (euchromatic histone lysine methyltransferase 1, mapped to chromosome 9q34) or by chromosomal deletions encompassing 9q34 and detected by chromosomal microarray or FISH — EHMT1 encodes a histone methyltransferase (also known as GLP, G9a-like protein) that catalyzes mono- and di-methylation of histone H3 at lysine 9 (H3K9me1 and H3K9me2), a repressive chromatin mark that establishes facultative heterochromatin at developmental gene loci requiring silencing during neural differentiation; EHMT1 forms an obligate heterodimeric complex with the closely related methyltransferase G9a (encoded by EHMT2), and together this EHMT1–EHMT2 complex establishes H3K9 methylation patterns that silence inappropriate neuronal gene programs during embryonic development, so that EHMT1 haploinsufficiency causes failure to repress gene programs that should be silenced in differentiating neurons — disrupting neural circuit formation, synaptic organization, and the transcriptional programs that normally coordinate social behavior, learning, and adaptive function; the molecular mechanisms producing Kleefstra Syndrome include intragenic EHMT1 point mutations, frameshift mutations, nonsense mutations (detectable by EHMT1 gene sequencing), chromosomal microdeletions of varying size encompassing 9q34.3 (detectable by chromosomal microarray or FISH; larger deletions may include additional genes contributing to phenotypic severity), and rarely whole-exon deletions or duplications detected by MLPA; the clinical phenotype includes moderate to severe intellectual disability with significant limitations in conceptual, social, and practical adaptive domains; characteristic facial features of prominent forehead, synophrys (connected eyebrows, a hallmark feature), hypertelorism, prognathism (prominent jaw) increasing with age, broad nasal bridge, midface hypoplasia, wide mouth with widely spaced teeth, and a brachydactyly pattern; childhood hypotonia frequently causing feeding difficulties in infancy; a behavioral profile that is perhaps the most clinically striking feature of Kleefstra Syndrome — the apparently happy, socially engaged, and affectionate personality characteristic of childhood that in a substantial proportion of individuals transitions in adolescence and young adulthood to social withdrawal, loss of communication skills, catatonia-like episodes, affective episodes, and a pattern clinically described as "Kleefstra Syndrome behavioral regression" or "regressive autism" — a phenotype that can be devastating for families who experienced many years of a child with a pleasant, engaging personality and now face a young adult who has lost skills and withdrawn from social interaction; epilepsy in approximately 30%; congenital heart defects in approximately 30% (ASD, VSD, pulmonary stenosis, aortic coarctation); urogenital anomalies including renal structural abnormalities, hydronephrosis, vesicoureteral reflux, and cryptorchidism; sleep disturbance affecting the majority of individuals; and strabismus, nystagmus, and other ophthalmological abnormalities; no FDA-approved disease-modifying therapy currently exists, with management consisting of EHMT1-appropriate seizure management, cardiac surgical or catheter-based intervention for structural defects, urological surveillance and intervention, behavioral support targeting the childhood-to-adolescence behavioral transition with psychiatric evaluation and pharmacotherapy for depression, catatonia, or anxiety during regression, and intensive developmental support.
Kleefstra Syndrome technology platforms — encompassing the molecular genetics laboratories where EHMT1 sequencing, chromosomal microarray, FISH, and MLPA establish the EHMT1 pathogenic variant or 9q34 deletion and enable genetic counseling (Kleefstra Syndrome is predominantly de novo with recurrence risk below 1% for unaffected parents, though parental chromosomal rearrangements can increase recurrence risk for deletion cases), the behavioral health and neuropsychiatric platforms where the critical Kleefstra adolescent/adult behavioral regression is detected, characterized, and managed with Vineland adaptive behavior assessments, psychiatric consultation, and pharmacotherapy, the pediatric neurology platforms managing the approximately 30% epilepsy burden, the cardiac monitoring platforms coordinating echocardiographic baseline assessment and cardiology follow-up for the 30% with structural cardiac defects, the urological monitoring platforms executing renal ultrasound surveillance and urological follow-up for urogenital anomalies, the sleep medicine platforms coordinating melatonin management and sleep hygiene for the prevalent sleep disturbance, and the rare disease registries and international Kleefstra natural history studies collecting longitudinal data on the behavioral regression phenotype — must maintain the availability and performance standards required by the behavioral regression surveillance imperative (detecting the adolescent/adult behavioral regression early enough to institute psychiatric evaluation and behavioral support before severe skill loss and catatonic withdrawal become entrenched), the cardiac and urological monitoring continuity required for the 30% of individuals with structural anomalies, and the sleep medicine coordination essential for a population with prevalent sleep disturbance. This guide explains why Kleefstra Syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the behavioral regression surveillance urgency, cardiac and urological monitoring requirements, epilepsy management needs, sleep medicine coordination, and rare disease registry participation of modern Kleefstra Syndrome care.
Why Kleefstra Syndrome Tech Platforms Require Specialized Monitoring Attention
Kleefstra Syndrome management is defined by several clinically urgent platform requirements: the behavioral regression surveillance imperative — the adolescent/adult Kleefstra behavioral regression representing loss of previously acquired social and communication skills, emergence of social withdrawal, catatonia-like episodes, and affective episodes is the most clinically consequential feature of Kleefstra Syndrome that is not present in childhood and that families are often unprepared for; early detection of emerging regression through systematic annual behavioral assessments using Vineland Adaptive Behavior Scales, comparison with prior assessments, and prompt psychiatric evaluation and pharmacotherapy (SSRIs for anxiety or depression, low-dose antipsychotics for catatonic features, mood stabilizers for affective episodes) represents the primary intervention capable of supporting function during the regression period; platform failures that interrupt annual behavioral assessment scheduling or that prevent Vineland score comparison with prior-year results delay the detection window during which regression can be identified, characterized, and treated; the cardiac monitoring continuity requirement for the 30% with structural defects — congenital heart defects requiring surgical correction or catheter-based intervention need consistent echocardiographic follow-up to monitor hemodynamic progression; the urological surveillance requirement for the subset with renal anomalies or hydronephrosis — hydronephrosis causing progressive renal damage requires surveillance ultrasound at defined intervals; and the sleep medicine coordination requirement for a population where sleep disturbance is prevalent and where untreated sleep disruption exacerbates behavioral challenges.
Behavioral regression surveillance platforms protect against delayed detection of Kleefstra adolescent/adult behavioral regression. Vineland adaptive behavior assessments, skill change documentation, and psychiatric referral coordination must be consistently executable. Monitor behavioral regression surveillance platforms at 1-minute intervals during clinical hours.
Cardiac monitoring platforms coordinate echocardiographic surveillance for structural defects in 30%. Congenital heart defect management and intervention planning require consistent cardiology platform access. Monitor cardiac platforms at 1-minute intervals during clinical hours.
Urological surveillance platforms monitor renal anomalies and hydronephrosis progression. Renal ultrasound scheduling and urological follow-up must be consistently maintained. Monitor urological platforms at 1-minute intervals during clinical hours.
Epilepsy management platforms coordinate seizure type characterization and AED management. The 30% epilepsy burden requires platform availability for EEG, AED management, and rescue medication coordination. Monitor epilepsy platforms at 1-minute intervals during clinical hours.
Sleep medicine platforms coordinate melatonin management and sleep assessment for prevalent sleep disturbance. Platform failures interrupt melatonin titration and sleep hygiene protocol access. Monitor sleep platforms at 2-minute intervals during clinical hours.
What to Monitor on a Kleefstra Syndrome Tech Platform
Behavioral Regression Surveillance — Adolescent/Adult Regression Detection
Monitor behavioral regression assessment records (annual Vineland Adaptive Behavior Scales-3 (Vineland-3) administration records — communication domain score, daily living skills domain score, socialization domain score, motor skills domain score; year-over-year score comparison documentation; statistical change thresholds for flagging clinically significant decline; behavioral informant interview records from caregivers and residential/educational staff), behavioral skill change documentation records (specific skill tracking — previously acquired conversational phrases, social initiation behaviors, play skills, ADL independence; documentation of skill loss onset timing and progression rate; catatonia feature checklist — mutism, akinesia, waxy flexibility, echolalia, stereotypies; affective episode documentation — mood change, sleep change, appetite change preceding behavioral regression onset), psychiatric consultation records (psychiatrist or developmental neuropsychiatrist consultation for regression — differential diagnosis of regression: Kleefstra behavioral regression vs. major depressive episode vs. psychotic episode vs. catatonia vs. hypothyroidism vs. seizure-related; pharmacotherapy records: SSRI for anxiety or depression, low-dose risperidone or aripiprazole for catatonic features, mood stabilizer for affective episodes; medication response and adverse effect documentation), and residential and day program behavioral observation records (staff-completed behavioral observation logs documenting social engagement frequency, participation in group activities, communication attempts, emotional presentation across the week) at 1-minute intervals during clinical hours. Alert immediately — behavioral regression surveillance platform failures during the annual Vineland-3 assessment for a 19-year-old Kleefstra male who was described by his group home staff as "withdrawing more over the last 6 months" — where the structured Vineland-3 comparison against his 18-year-old assessment might reveal a clinically significant decline in the socialization domain that would trigger psychiatric referral and pharmacotherapy consideration during the window when behavioral intervention has the best chance of supporting function before severe catatonic withdrawal becomes entrenched.
Cardiac Monitoring — Structural Defects in 30%
Monitor echocardiogram records (baseline echocardiogram at Kleefstra diagnosis — structural anomaly characterization: ASD size and hemodynamic significance; VSD size and pulmonary pressure estimate; pulmonary stenosis gradient; aortic coarctation gradient; echocardiogram comparison across serial studies), cardiology follow-up records (annual cardiology review for Kleefstra individuals with documented structural defects — hemodynamic progression assessment; surgical or catheter-based intervention threshold documentation; post-intervention follow-up records), endocarditis prophylaxis records (antibiotic prophylaxis guidance for Kleefstra individuals with unrepaired defects or post-intervention residua undergoing dental or surgical procedures), and cardiac symptom documentation records (exercise intolerance, dyspnea, cyanosis, heart failure symptoms — clinical flags triggering cardiology review frequency escalation) at 1-minute intervals during clinical hours. Alert immediately — cardiac monitoring platform failures preventing the retrieval of serial echocardiographic measurements for a 5-year-old Kleefstra female with a moderate secundum ASD — where the pediatric cardiologist needs to compare right heart dimensions on the current echocardiogram with measurements from 12 months ago to determine whether progressive right ventricular volume overload has crossed the threshold for recommending transcatheter ASD closure.
Urogenital Anomaly Monitoring — Renal and Urological Surveillance
Monitor renal ultrasound records (baseline renal ultrasound at Kleefstra diagnosis — hydronephrosis grading: SFU grades 1–4; renal size measurement; cortical thickness; parenchymal echogenicity; interval renal ultrasound scheduling based on hydronephrosis severity — grades 1–2: annual ultrasound; grades 3–4: more frequent surveillance with urological co-management; unilateral vs. bilateral involvement), urological follow-up records (MAG3 renal scan for functional assessment and drainage studies in hydronephrosis grade 3–4; vesicoureteral reflux voiding cystourethrogram records; ureteral reimplantation or pyeloplasty surgical records for obstructive uropathy), blood pressure monitoring records (hypertension screening annually — renal parenchymal disease and renal artery anomalies in Kleefstra can contribute to hypertension; ambulatory blood pressure monitoring records for borderline elevation), renal function records (annual serum creatinine, BUN, and estimated GFR; urinalysis with proteinuria screening; nephrology referral for progressive renal impairment), and cryptorchidism management records (orchidopexy surgical records for undescended testes; testicular ultrasound records; fertility counseling documentation for adolescent males) at 1-minute intervals during clinical hours. Alert immediately — urological platform failures preventing the MAG3 renal scan scheduling for a 3-year-old Kleefstra male with bilateral hydronephrosis grade 3 — where the functional drainage study is needed to determine the differential function between the two kidneys and whether obstructive uropathy on the more severely affected side has caused differential functional impairment requiring pyeloplasty.
Epilepsy Management — Seizure Diary and AED Protocol
Monitor seizure diary records (parental seizure diary — seizure type in Kleefstra context: generalized tonic-clonic, myoclonic, absence, atonic; seizure frequency; seizure duration; AED response; breakthrough seizure documentation), EEG records (baseline EEG; video-EEG for seizure type characterization; ambulatory EEG for seizure burden quantification), AED management records (valproate: serum level, hepatic monitoring; levetiracetam: dose, behavioral adverse effects including irritability requiring monitoring in a Kleefstra individual with behavioral phenotype considerations; lamotrigine: rash monitoring, slow titration protocol; AED combination optimization), rescue medication records (rectal diazepam or intranasal midazolam prescription and refill; seizure action plan for caregivers and day program staff), and neurology follow-up records (annual neurology review; EEG comparison; AED dose review) at 1-minute intervals during clinical hours.
Sleep Medicine — Melatonin Management and Sleep Disturbance
Monitor sleep diary records (caregiver sleep log — sleep onset latency, night waking frequency and duration, total sleep time, early morning awakening; sleep diary comparison across months; caregiver burden documentation from sleep disruption), melatonin management records (dose titration — 0.5–10 mg melatonin; immediate-release vs. extended-release formulation selection based on Kleefstra individual's sleep onset vs. sleep maintenance pattern; timing protocol — 30–60 minutes before target bedtime; response documentation), sleep pharmacotherapy records (clonidine or low-dose trazodone for refractory sleep initiation; mirtazapine for combined sleep and appetite issues; medication response and behavioral adverse effect monitoring), polysomnography records (sleep study for Kleefstra individuals with suspected sleep-disordered breathing or excessive daytime sleepiness — AHI, oxygen saturation nadir, sleep architecture assessment), and sleep hygiene protocol records (Kleefstra-adapted bedtime routine: reduced screen light exposure, consistent routine, environmental light and sound management) at 2-minute intervals during clinical hours.
Developmental Records and Ophthalmological Monitoring
Monitor developmental and educational records (IEP annual records; educational placement documentation; adaptive behavior testing — Vineland-3 annually for regression surveillance; speech and language assessment — AAC evaluation where verbal communication has regressed; OT and PT therapy logs), ophthalmological records (annual eye exam — strabismus assessment; nystagmus documentation; refractive error; amblyopia treatment; referral to strabismus surgery if indicated), and behavioral support plan records (behavioral support plan documentation for day program and residential settings; positive behavioral support strategies; crisis de-escalation plan for catatonic episodes) at 2-minute intervals during business hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Kleefstra Syndrome management coordinates across molecular genetics (EHMT1 characterization, 9q34 deletion analysis), behavioral health and neuropsychiatry (behavioral regression detection and pharmacotherapy), pediatric neurology (epilepsy), cardiology (structural cardiac defects), urology and nephrology (urogenital anomalies), sleep medicine (sleep disturbance), developmental pediatrics, occupational therapy, physical therapy, speech-language pathology, ophthalmology, and special education — authentication failures block every specialist required to detect behavioral regression early, maintain cardiac and urological surveillance, and coordinate seizure management.
SSL Certificates
Monitor SSL certificate expiry across all behavioral health platforms, cardiac monitoring systems, urological surveillance platforms, epilepsy management systems, molecular genetics portals, and sleep medicine platforms. Certificate errors disrupting behavioral regression assessment access carry direct patient safety implications for a population whose most serious clinical complication — adolescent behavioral regression — requires consistent annual assessment surveillance to detect.
HIPAA and Genomic Privacy Considerations for Kleefstra Syndrome
Kleefstra Syndrome technology platforms handle EHMT1 pathogenic variant results and 9q34 chromosomal microarray data under HIPAA Privacy Rule protections. The predominantly de novo EHMT1 variants carry low parental recurrence risk, but chromosomal deletion cases where a parental translocation is identified carry higher recurrence risk, requiring careful genetic counseling records management.
Kleefstra Syndrome individuals with moderate to severe intellectual disability and behavioral regression require legal guardianship documentation maintained across all care platforms when they reach the age of majority, with clear procedures for authorized representative access to behavioral regression assessment records, psychiatric pharmacotherapy records, and residential behavioral observation logs. The sensitive nature of psychiatric pharmacotherapy records for behavioral regression (SSRI, antipsychotic, mood stabilizer prescriptions) requires appropriate access controls distinguishing clinical team access from unauthorized third-party access.
Alerting Strategy for Kleefstra Syndrome Tech Platforms
Immediate clinical-hours alerting for behavioral regression surveillance platforms: Annual Vineland-3 assessment scheduling and year-over-year comparison are time-sensitive for detecting Kleefstra behavioral regression at an early stage; platform failures interrupting annual assessment scheduling delay the regression detection window.
Immediate clinical-hours alerting for cardiac monitoring platforms: Echocardiographic surveillance and cardiology follow-up for structural defects in 30% require consistent scheduling access.
Immediate clinical-hours alerting for urological surveillance platforms: Hydronephrosis surveillance ultrasound scheduling and functional drainage study access are clinically time-sensitive for renal protective management.
Immediate clinical-hours alerting for epilepsy management platforms: Seizure diary review, EEG scheduling, and AED management require consistent platform access.
Sustained-failure alert (10–15 minutes): Sleep medicine coordination, developmental records, IEP management, ophthalmological monitoring, and rare disease registry platforms.
30-day advance warning: SSL certificates across all behavioral health, cardiac, urological, epilepsy, and molecular testing platforms.
Vigilmon's multi-region monitoring confirms Kleefstra platform availability from the geographic regions where EHMT1 molecular testing laboratories, Kleefstra specialty centers, behavioral regression management programs, and pediatric cardiology and urology services concentrate.
Status Page for Kleefstra Syndrome Care Team Communication
A real-time status page gives EHMT1 molecular geneticists confirming pathogenic variant or 9q34 deletion, behavioral health and neuropsychiatry teams detecting and managing behavioral regression, pediatric neurologists managing Kleefstra epilepsy, pediatric cardiologists monitoring structural defects, urologists and nephrologists managing renal anomalies, sleep medicine physicians coordinating sleep disturbance management, and caregivers navigating multi-specialty coordination immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in behavioral regression assessment backup procedures, cardiac monitoring downtime protocols, urological surveillance emergency procedures, and epilepsy clinic downtime documentation.
Vigilmon Setup for Kleefstra Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Behavioral regression surveillance (Vineland-3, skill tracking, psychiatric referral) | 1 min | Slack + PagerDuty (clinical hours) | | Echocardiogram and cardiology follow-up (structural defects in 30%) | 1 min | Slack + PagerDuty (clinical hours) | | Renal ultrasound surveillance (hydronephrosis, urogenital anomalies) | 1 min | Slack + PagerDuty (clinical hours) | | MAG3 renal scan and functional drainage studies | 1 min | Slack + PagerDuty (clinical hours) | | Blood pressure monitoring and renal function (GFR, urinalysis) | 1 min | Slack + PagerDuty (clinical hours) | | Seizure diary and EEG records | 1 min | Slack + PagerDuty (clinical hours) | | AED management (valproate, levetiracetam, lamotrigine) | 1 min | Slack + PagerDuty (clinical hours) | | Rescue medication and seizure action plan | 1 min | Slack + PagerDuty (24/7) | | EHMT1 molecular genetics (sequencing, 9q34 microarray) | 1 min | Slack + PagerDuty (lab hours) | | Sleep diary and melatonin management | 2 min | Slack (clinical hours) | | Polysomnography scheduling | 2 min | Slack (clinical hours) | | Developmental records and IEP coordination | 2 min | Slack (business hours) | | Ophthalmology (strabismus, nystagmus) | 2 min | Slack (business hours) | | Rare disease registry and natural history study | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure behavioral regression surveillance platforms with immediate clinical-hours alerting — the highest patient safety priority in the Kleefstra care ecosystem
- Add echocardiogram and cardiology follow-up platforms with immediate clinical-hours alerting
- Configure renal ultrasound surveillance with immediate clinical-hours alerting
- Add MAG3 renal scan and functional drainage study platforms with immediate clinical-hours alerting
- Configure blood pressure monitoring and renal function platforms with immediate clinical-hours alerting
- Add seizure diary and EEG platforms with immediate clinical-hours alerting
- Configure AED management platforms with immediate clinical-hours alerting
- Add rescue medication and seizure action plan platforms with 24/7 immediate alerting
- Configure EHMT1 molecular genetics platforms with immediate laboratory-hours alerting
- Add sleep diary and melatonin management platforms with sustained-failure alerting
- Configure polysomnography scheduling with sustained-failure alerting
- Add developmental records and IEP coordination platforms with sustained-failure alerting
- Configure ophthalmology platforms with sustained-failure alerting
- Add rare disease registry platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all behavioral health, cardiac, urological, epilepsy, and molecular testing platforms
- Add the status page URL to behavioral regression assessment backup procedures, cardiac monitoring downtime protocols, and urological surveillance emergency documentation
Conclusion
Kleefstra Syndrome technology platforms are embedded in clinical decisions where behavioral regression surveillance platform availability during the annual Vineland-3 assessment for a 21-year-old EHMT1-confirmed Kleefstra male who lives in a supported residential setting — when the group home behavioral documentation system is temporarily unavailable and the validated Vineland-3 assessment cannot be completed with caregiver informant data on the scheduled date — directly affects the probability of detecting the emerging social withdrawal and communication skill loss that began four months ago and that, if identified now through the Vineland-3 comparison with last year's scores, would trigger a psychiatric consultation capable of characterizing whether the emerging regression represents a Kleefstra-specific behavioral regression episode, a major depressive episode superimposed on intellectual disability, or early catatonic features amenable to low-dose risperidone, SSRI, or lorazepam intervention during the window when behavioral treatment can prevent further skill loss; where echocardiographic follow-up platform availability during the annual cardiology appointment for a 6-year-old Kleefstra female with a moderate-sized secundum ASD — when the echocardiogram viewing platform is unavailable and the pediatric cardiologist cannot compare the current right ventricular dimension measurements with last year's study — prevents the cardiology assessment from determining whether progressive right ventricular volume overload has crossed the threshold for recommending transcatheter ASD closure, with the consequence that the clinical decision about intervention timing cannot be made during the appointment when the family has traveled to the children's cardiac center; and where urological surveillance platform availability for a 4-year-old Kleefstra male with bilateral hydronephrosis grade 3 — when the renal ultrasound scheduling system is unavailable during the urology clinic appointment and the follow-up ultrasound required at the 6-month interval cannot be ordered — delays the imaging assessment needed to determine whether his differential renal function has remained stable or has declined on the side with more severe hydronephrosis, where functional loss would change the urgency of the surgical intervention recommendation. A Kleefstra behavioral regression surveillance platform unavailable during the annual Vineland-3 assessment, a cardiac monitoring platform interrupted during an echocardiographic follow-up appointment, a urological surveillance scheduling system unavailable during a urology clinic visit — these are not IT incidents. They are clinical disruptions in the management of a disorder whose most serious adult complication — behavioral regression — requires annual systematic assessment to detect, whose cardiac anomalies require consistent echocardiographic follow-up to manage, and whose urological anomalies require scheduled surveillance imaging to protect renal function.
Uptime monitoring gives Kleefstra Syndrome tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to EHMT1 molecular testing laboratories, behavioral health and neuropsychiatry programs, pediatric cardiology and urology services, epilepsy clinics, sleep medicine practices, and compliance auditors that platform operational reliability matches the behavioral regression surveillance urgency, cardiac and urological monitoring requirements, and epilepsy management needs of modern Kleefstra Syndrome care.
Start monitoring your Kleefstra Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #kleefstra #syndrome #EHMT1 #9q34 #deletion #H3K9 #methyltransferase #GLP #G9a #EHMT2 #behavioral #regression #catatonia #intellectual #disability #epilepsy #cardiac #hydronephrosis #sleep #neurodevelopmental #HIPAA #healthtech #digitalhealth #uptime #sre